Nomura Holdings Inc. Invests $15.01 Million in Thermo Fisher Scientific Inc. (NYSE:TMO)

Nomura Holdings Inc. bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 28,269 shares of the medical research company’s stock, valued at approximately $15,005,000.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Thermo Fisher Scientific by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock worth $16,582,503,000 after buying an additional 180,618 shares during the period. Morgan Stanley grew its position in shares of Thermo Fisher Scientific by 0.4% during the 3rd quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock worth $6,285,838,000 after buying an additional 50,736 shares during the period. Capital Research Global Investors grew its position in shares of Thermo Fisher Scientific by 6.9% during the 4th quarter. Capital Research Global Investors now owns 7,989,614 shares of the medical research company’s stock worth $4,240,824,000 after buying an additional 517,137 shares during the period. Norges Bank acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $2,909,524,000. Finally, Northern Trust Corp grew its position in shares of Thermo Fisher Scientific by 2.6% during the 3rd quarter. Northern Trust Corp now owns 3,929,225 shares of the medical research company’s stock worth $1,988,856,000 after buying an additional 99,377 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 0.2 %

Shares of Thermo Fisher Scientific stock opened at $569.17 on Wednesday. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The stock has a market cap of $217.26 billion, a P/E ratio of 36.51, a P/E/G ratio of 2.65 and a beta of 0.79. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The business’s 50 day moving average is $574.54 and its 200-day moving average is $559.84.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Analysts Set New Price Targets

Several research firms have recently issued reports on TMO. JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. HSBC boosted their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. The Goldman Sachs Group boosted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Barclays boosted their price objective on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research report on Thursday, April 25th. Finally, Citigroup began coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $607.94.

Insider Transactions at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The disclosure for this sale can be found here. Insiders have sold a total of 22,000 shares of company stock worth $12,532,780 in the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.